M&A Deals: Monthly Monitor November

2 December 2015

November – The year 2015 is set to go down as the biggest ever in terms of acquisitions deals as pharma giant Pfizer (NYSE: PFE) and Botox-maker Allergan (NYSE: AGN) set out to create the largest drug company in the world. Valued at $160 billion, the deal comes close on the heels of Pfizer’s $17 billion acquisition of Hospira and a failed attempt to grab UK drug major AstraZeneca (LSE: AZN).

The total deal vale for the year so far has touched $3.29 trillion, ahead of the $3.27 trillion recorded for the full-year 2014, according to data from Mergermarket. Given the pace of M&A activity it may not be wrong to estimate the year is likely to surpass the record deal value of $3.67 trillion witnessed in the year 2007.

Overall, a series of other big ticket deals in the pharma/biotech sector has marked the year as the strongest period of mergers and acquisition activity.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK